Table 3.
Research Evaluation Incidence n(%) | Clinical Evaluation Incidence n(%) | Kappa* | |
---|---|---|---|
7 Days of Age | 59 (31.4) | 38 (20.2) | 0.54 |
36 Weeks PMA | 28 (15.6) | 32 (17.8) | 0.80 |
Research and Clinical PH were determined to exist if Right Ventricular Hypertrophy,
Right Ventricular Dilation or Septal Wall Flattening were present. All PABAK values were calculated comparing Research PH and Clinical PH incidence values.